Caplin Point Laboratories Limited Share Price NSE India S.E.

Equities

CAPLIPOINT

INE475E01026

Pharmaceuticals

Market Closed - NSE India S.E. 05:10:29 24/04/2024 pm IST 5-day change 1st Jan Change
1,336 INR +0.10% Intraday chart for Caplin Point Laboratories Limited +1.50% -1.49%
Sales 2024 * 16.92B 203M Sales 2025 * 19.11B 229M Capitalization 101B 1.21B
Net income 2024 * 4.57B 54.87M Net income 2025 * 4.17B 50.08M EV / Sales 2024 * 5.98 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 5.29 x
P/E ratio 2024 *
22.3 x
P/E ratio 2025 *
20.7 x
Employees 1,642
Yield 2024 *
0.24%
Yield 2025 *
0.26%
Free-Float 25.33%
More Fundamentals * Assessed data
Dynamic Chart
Caplin Point Arm Gets US FDA Final Nod for Ofloxacin Ophthalmic Solution MT
Caplin Point Unit Receives US FDA Nod for Eye Treatment Medication MT
Caplin Steriles Limited, A Subsidiary of Caplin Point Laboratories Limited Gets USFDA Approval for Ketorolac Tromethamine Ophthalmic Solution CI
Caplin Point Laboratories Arm Starts Operations of Oncology Facility at Kakkalur, India MT
Caplin One Labs Limited, a Wholly Owned Subsidiary of Caplin Point Laboratories Limited Successfully Completes New Oncology (Anti-Cancer) Facility, Commences Operations CI
Transcript : Caplin Point Laboratories Limited, Q3 2024 Earnings Call, Feb 09, 2024
Caplin Point Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Caplin Point Laboratories to Invest INR7 Billion in Tamil Nadu, India MT
Caplin Point Unit Gets US FDA Final Approval for Generic Ear Infection Drug MT
Caplin Point Laboratories Limited Announces Resignation of Hero Velladurai as President, R&D CI
Transcript : Caplin Point Laboratories Limited, H1 2024 Earnings Call, Nov 09, 2023
Caplin Point Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Caplin Point Laboratories Limited Approves Final Dividend for the Year Ended March 31, 2023 CI
Caplin Point Unit's Injectable and Ophthalmic Plant in India Gets VAI Classification from US FDA MT
Transcript : Caplin Point Laboratories Limited, Q1 2024 Earnings Call, Aug 08, 2023
More news
1 day+0.10%
1 week+1.50%
Current month+1.57%
1 month+5.30%
3 months-11.18%
6 months+33.95%
Current year-1.49%
More quotes
1 week
1 290.00
Extreme 1290
1 354.95
1 month
1 240.00
Extreme 1240
1 409.90
Current year
1 240.00
Extreme 1240
1 619.05
1 year
646.80
Extreme 646.8
1 619.05
3 years
485.25
Extreme 485.25
1 619.05
5 years
176.20
Extreme 176.2
1 619.05
10 years
34.20
Extreme 34.2
1 619.05
More quotes
Managers TitleAgeSince
Chief Executive Officer 69 28/15/28
Director of Finance/CFO - 19/16/19
Chief Administrative Officer - -
Members of the board TitleAgeSince
Chairman 71 -
Chief Operating Officer - 01/10/01
Chief Executive Officer 69 28/15/28
More insiders
Date Price Change Volume
24/24/24 1,336 +0.10% 50 158
23/24/23 1,335 -0.24% 64,347
22/24/22 1,338 +2.00% 74,419
19/24/19 1,312 -0.36% 72,593
18/24/18 1,316 +0.02% 102,719

Delayed Quote NSE India S.E., April 24, 2024 at 05:10 pm IST

More quotes
Caplin Point Laboratories Limited is an India-based pharmaceutical company. The Company is engaged in producing, developing, and marketing a range of generic formulations and branded products and exporting to overseas markets. Its products include tablets, dry syrups (bottles), soft gels, capsules, suppositories, liquid syrups (bottles), liquid injectables in ampoules and vials, lyophilized vials, prefilled syringes (PFS), emulsion injection in ampoules and vials, ophthalmic droppers, pre-mix bags, topicals and sachets (liquids and powders). It also manufactures a range of ointments, creams, gels and lotions. Its principal research and development facilities are in Tamil Nadu, India. Its principal manufacturing facility is in Puducherry, India. It has presence in Latin America (LATAM), Southern Africa and Francophone Africa along with a presence in United States of America and European region. The Company’s subsidiaries include Caplin Point Far East Limited and Caplin Steriles Limited.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1,332 INR
Average target price
1,579 INR
Spread / Average Target
+18.55%
Consensus

Quarterly revenue - Rate of surprise